Ibrance (palbociclib; Pfizer) is a small-molecule inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). When associated with cyclin-D proteins, CDK4/6 are able to phosphorylate and inactivate.
Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER).
CSL’s MF-59 adjuvanted QIV is a subunit, surface antigen-containing seasonal QIV adjuvanted withMF59. It contains antigens from two A strains and two B strains specified by the World HealthOrganization seasonally for seasonal influenza vaccination.
Novavax’s virus-like particle (VLP) quadrivalent influenza vaccine (QIV), currently in Phase II
development, has the potential for significant market success if it is able to demonstrate superior
safety or efficacy data in Phase III studies.
Ampyra is a potassium channel blocker, marketed by Acorda Therapeutics and Biogen, which is
approved to improve walking ability in multiple sclerosis patients. Although Ampyra’s active molecule
fampridine (4-aminopyridine) is readily available, by using Elan’s Intestinal Protective Drug Absorption
System, Acorda has developed a sustained-released oral tablet formulation allowing twice-daily
dosing.
Zaltrap is a human recombinant fusion protein comprising segments of the human VEGFRs 1 and 2 and the Fc portion of the human immunoglobulin G1 (Tang et al., 2008).
Peretinoin (Kowa/Chugai Pharmaceutical) is a synthetic acyclic retinoid inhibitor of transforming growth factor alpha (TGF-alpha) and platelet-derived growth factor receptor (PDGFR). TGF-alpha induces epithelial development, and is closely involved in hepatocarcinogenesis.
Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.
F/TAF (emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a fixed-dose combination of two of Gilead’s nucleoside reverse transcriptase inhibitors, Emtriva (emtricitabine) and GS-7340 (TAF).
D/C/F/TAF is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), the two nucleoside reverse transcriptase inhibitors…
Tybost (cobicistat; Gilead) is a boosting agent to be used in combination with protease inhibitors (PIs) as part of treatment regimens for HIV-1 infection.
Recentin (cediranib; AstraZeneca) is a small molecule inhibitor of all three vascular endothelial growth factor receptor (VEGFR-1, -2, -3) tyrosine kinases.
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs.
ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!